Dovonex Psoriasis 50 microgram/g ointment *
Pharmacy Only: Non-prescription

  • Company:

    LEO Pharma
  • Status:

    No Recent Update
  • Legal Category:

    Supply through pharmacy only
  • Active Ingredient(s):

    *Additional information is available within the SPC or upon request to the company

Updated on 06 July 2020

File name

ie-mockup-pl dovonex psoriasis excip_1594025427.pdf

Reasons for updating

  • Change to section 2 - excipient warnings
  • Change to section 4 - how to report a side effect
  • Change to section 6 - date of revision

Updated on 06 July 2020

File name

ie-spc clean dovonex psoriasis_1594024816.pdf

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category:Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

- In section 2 the quantity of propylene glycol has been added

- In section 4.8 the reporting of side effects statement has been updated in accordance with the latest version of Annex 5

Updated on 13 February 2020

File name

ie-pl-dovonex psoriasis ointment-paraffin_1581590509.pdf

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 6 - date of revision
  • Addition of information on alternative format leaflets

Updated on 07 December 2016

Reasons for updating

  • New SPC for new product

Legal category:Supply through pharmacy only

Updated on 07 December 2016

Reasons for updating

  • Change to section 10 - Date of revision of the text
  • Change to section 5.1 - Pharmacodynamic properties

Legal category:Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Section 5.1 and 10 updated as follows;


5.1      
Pharmacodynamic properties

ATC Code: D05A X02

Pharmacotherapeutic group: Other antipsoriatics for topical use

Calcipotriol is a vitamin D derivative.  In vitro data suggest that calcipotriol induces differentiation and suppresses proliferation of keratinocytes.  This is the proposed basis for its effect in psoriasis. A clinical improvement usually starts to become apparent after two weeks’ treatment.

 

10        DATE OF REVISION OF THE TEXT

April 2016 December 2016

Updated on 27 June 2016

File name

PIL_16733_458.pdf

Reasons for updating

  • New PIL for new product

Updated on 27 June 2016

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to date of revision

Updated on 17 May 2016

Reasons for updating

  • New SPC for new product

Legal category:Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

None provided

Updated on 13 May 2016

Reasons for updating

  • New PIL for new product